These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34880797)

  • 1. Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms.
    Vasiliu O
    Front Psychiatry; 2021; 12():786171. PubMed ID: 34880797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case series: Cariprazine in early-onset schizophrenia.
    Ivanova E; Maslinkova D; Polnareva N; Milanova V
    Front Psychiatry; 2023; 14():1155518. PubMed ID: 37124247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).
    Ivanov SV; Smulevich AB; Voronova EI; Yakhin KK; Beybalaeva TZ; Katok AA
    Front Psychiatry; 2021; 12():770592. PubMed ID: 35140638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study)].
    Smulevich AB; Ivanov SV; Yakhin KK; Voronova EI; Kharkova GS; Skurygina EI; Konohova MV; Beybalaeva TZ; Katok AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12):67-72. PubMed ID: 33459543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study.
    Yeung PP; Johnson KA; Riesenberg R; Orejudos A; Riccobene T; Kalluri HV; Malik PR; Varughese S; Findling RL
    J Child Adolesc Psychopharmacol; 2023 Aug; 33(6):232-242. PubMed ID: 37437109
    [No Abstract]   [Full Text] [Related]  

  • 8. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.
    Fleischhacker W; Galderisi S; Laszlovszky I; Szatmári B; Barabássy Á; Acsai K; Szalai E; Harsányi J; Earley W; Patel M; Németh G
    Eur Psychiatry; 2019 May; 58():1-9. PubMed ID: 30738380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
    Németh G; Laszlovszky I; Czobor P; Szalai E; Szatmári B; Harsányi J; Barabássy Á; Debelle M; Durgam S; Bitter I; Marder S; Fleischhacker WW
    Lancet; 2017 Mar; 389(10074):1103-1113. PubMed ID: 28185672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
    Earley W; Guo H; Daniel D; Nasrallah H; Durgam S; Zhong Y; Patel M; Barabássy Á; Szatmári B; Németh G
    Schizophr Res; 2019 Feb; 204():282-288. PubMed ID: 30172595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia.
    Selvan P; Devkare P; Shetty A; Dharmadhikari S; Khandhedia C; Mane A; Mehta S; Andrade C
    Front Psychiatry; 2024; 15():1385925. PubMed ID: 38711874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
    Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.
    Laszlovszky I; Barabássy Á; Németh G
    Adv Ther; 2021 Jul; 38(7):3652-3673. PubMed ID: 34091867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical issues with amisulpride in the management of patients with schizophrenia.
    Pani L; Villagrán JM; Kontaxakis VP; Alptekin K
    Clin Drug Investig; 2008; 28(8):465-77. PubMed ID: 18598092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine in the management of emotionally unstable personality disorder in female patients: a case series.
    Pappa S; Caldwell-Dunn E; Kalniunas A; Kamal M
    Front Psychiatry; 2024; 15():1421698. PubMed ID: 39132320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia.
    Riccobene T; Riesenberg R; Yeung PP; Earley WR; Hankinson AL
    J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):434-443. PubMed ID: 36282772
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.